- Home
- CCS vs JANX Comparison
CCS vs JANX Comparison
Compare CCS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- JANX
- Stock Information
- Founded
- CCS 2000
- JANX 2017
- Country
- CCS United States
- JANX United States
- Employees
- CCS N/A
- JANX N/A
- Industry
- CCS Homebuilding
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- JANX Health Care
- Exchange
- CCS Nasdaq
- JANX Nasdaq
- Market Cap
- CCS 1.7B
- JANX 1.6B
- IPO Year
- CCS 2014
- JANX 2021
- Fundamental
- Price
- CCS $55.62
- JANX $23.72
- Analyst Decision
- CCS Buy
- JANX Strong Buy
- Analyst Count
- CCS 4
- JANX 7
- Target Price
- CCS $101.33
- JANX $94.29
- AVG Volume (30 Days)
- CCS 412.6K
- JANX 953.5K
- Earning Date
- CCS 04-23-2025
- JANX 05-08-2025
- Dividend Yield
- CCS 2.10%
- JANX N/A
- EPS Growth
- CCS 7.67
- JANX N/A
- EPS
- CCS 9.70
- JANX N/A
- Revenue
- CCS $4,352,977,000.00
- JANX $9,336,000.00
- Revenue This Year
- CCS $9.22
- JANX N/A
- Revenue Next Year
- CCS $7.74
- JANX $250.58
- P/E Ratio
- CCS $5.70
- JANX N/A
- Revenue Growth
- CCS 11.97
- JANX 28.12
- 52 Week Low
- CCS $52.41
- JANX $22.52
- 52 Week High
- CCS $108.42
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CCS 40.71
- JANX 34.96
- Support Level
- CCS $52.85
- JANX $22.48
- Resistance Level
- CCS $58.31
- JANX $28.13
- Average True Range (ATR)
- CCS 1.73
- JANX 2.20
- MACD
- CCS 0.53
- JANX -0.73
- Stochastic Oscillator
- CCS 38.27
- JANX 9.05
About CCS Century Communities Inc.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.